Table 2.
Summary of TANTALUS® trials
| Ref.1 | Sample size (n), enrolled/completed | Mean age (yr) | Mean weight, (kg)/mean BMI (kg/m2) | Follow-up (mo) | Lifestyle change (required/advice given) | Co-morbidities |
| Lebovitz et al[38], 2013 | 40/40 | NR | 110.5 ± 3.5/NR | NR | NR/NR | NR |
| Sanmiguel et al[70], 2009 | 14/11 | 42 | 107.3 ± 20.1/39 ± 1 | 6 | N/Y | T2DM |
| Bohdjalian et al[39], 2009 | 24/21 | 50.0 ± 1.6 | 123.7 ± 4.5/41.9 ± 1.0 | 12 | NR/NR | T2DM |
| Policker et al[37], 2009 | 50/50 | NR | NR/NR | 6+ | NR/NR | T2DM |
| Bohdjalian et al[71], 2009 | 13/13 | 53.8 ± 2.6 | 104.4 ± 4.4/37.2 ± 1.1 | 3 | N/Y | T2DM |
| Policker et al[69], 2008 | 12/12 | 50.8 ± 2.2 | 130 ± 6.5/NR | 9 | N/Y | T2DM |
| Sanmiguel et al[43], 2007 | 12/11 | 39.1 ± 8.9 | NR/41.6 ± 3.4 | 1.5 | N/NR | T2DM |
| Bohdjalian et al[72], 2006 | 12/9 | 36.1 ± 2.8 | 128.8 ± 5.2/43.2 ± 2.7 | 12 | N/Y | HTN |
1
All trials were open-label and none were randomized. T2DM: Type 2 diabetes.